Arrowhead Pharmaceuticals: Plozasiran as a Game Changer – Will Arrowhead Become the Second Major Player in the RNAi Market?

Market penetration for RNAi-based therapies is imminent. Back in November 2024, I reported that Arrowhead could become Alnylam's first competitor in the RNAi market as early as 2025. The signs for this continue to grow. A decision on FDA approval for the product candidate Plozasiran will be made by November 18. The first drug approval by the US Food and Drug Administration would secure long-term growth potential for the company in a severely underserved market. Arrowhead's latest announcements in this regard have caused the share price to rise by...